Detalles de la búsqueda
1.
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Antimicrob Agents Chemother
; 66(5): e0139921, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35471040
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022730
3.
Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33318005
4.
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Crit Care
; 25(1): 354, 2021 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34600585
5.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care
; 25(1): 290, 2021 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380538
6.
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Am J Perinatol
; 38(8): 804-809, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31910460
7.
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
J Antimicrob Chemother
; 75(6): 1546-1553, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32211756
8.
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Br J Clin Pharmacol
; 86(5): 944-957, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31856304
9.
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Antimicrob Agents Chemother
; 63(6)2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30962340
10.
The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
J Infect Chemother
; 25(2): 104-110, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420153
11.
The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
J Infect Chemother
; 25(2): 111-116, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30528561
12.
Intrapulmonary Pharmacokinetics of Relebactam, a Novel ß-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29311084
13.
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a ß-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29914955
14.
Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps.
Curr Ther Res Clin Exp
; 84: 22-25, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28761575
15.
Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Antimicrob Agents Chemother
; 58(3): 1294-301, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24295974
16.
Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a ß-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
Antimicrob Agents Chemother
; 62(12)2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478180
17.
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.
J Virol
; 86(19): 10862-5, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22811531
18.
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
J Clin Pharmacol
; 63(2): 166-171, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36046982
19.
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
J Clin Pharmacol
; 63(3): 352-357, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36201105
20.
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Pediatr Infect Dis J
; 42(7): 557-563, 2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37000942